Mark Breidenbach

Analyst-Equity chez Oppenheimer & Co., Inc. (Broker)

Profil

Dr. Mark Breidenbach is Executive Director & Senior Analyst at Oppenheimer & Co., Inc. He covers Emerging Biotechnology.
Prior to joining the firm, Dr. Breidenbach worked at Roth Capital Partners as a lead Analyst covering Biotechnology and prior to that was a Managing Director and Senior Biotechnology Analyst at H.C.
Wainwright & Co. Prior to his Wall Street career, he was a Locum Scientist at Nature Publishing Group, and an Associate Specialist in Glycoproteomics and Metabolic Engineering at the Department of Chemistry, University of California Berkeley.
He holds a Ph.D.
in Molecular and Cellular Physiology from Stanford University, a M.
Phil.
from the Department of Molecular Biophysics and Biochemistry at Yale University, and a dual B.A.
in Biology and Chemistry from Cornell University.

Postes actifs de Mark Breidenbach

Sociétés	Poste	Début
Oppenheimer & Co., Inc. (Broker)	Analyst-Equity	01/05/2017

Anciens postes connus de Mark Breidenbach

Sociétés	Poste	Fin
ROTH Capital Partners LLC	Analyst-Equity	01/05/2017
H. C. Wainwright & Co. LLC	Analyst-Equity	01/07/2016
Redwood Bioscience, Inc.	Corporate Officer/Principal	28/02/2013
University of California, Berkeley	Corporate Officer/Principal	31/10/2012

Formation de Mark Breidenbach

Yale University	Graduate Degree
Cornell University	Undergraduate Degree
Stanford University	Doctorate Degree